Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster

Landsberg, Hannah E.; Turcinovic, Jacquelyn; Sullivan, Madison; Connor, John H.; Hamer, Davidson H.; Platt, Judy

doi:10.1016/j.ijid.2021.10.053

Cited by 4 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study on matched anterior nares swabs tested with both RT-PCR and Abbott BinaxNOW TM (Abbott Laboratories, Chicago, IL) was critical during the omicron surge as the demand for rapid diagnostic tests increased [28] . Data from the BU CTL, contact tracing, and sequencing data provided insight on vaccine efficacy [30] , transmission of SARS-CoV-2 in classrooms [31] , post-quarantine transmission and quarantine length [32] , and isolation release after infection [33] .…”

Section: Resultsmentioning

confidence: 99%

Buildout and integration of an automated high-throughput CLIA laboratory for SARS-CoV-2 testing on a large urban campus

et al. 2022

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Buildout and integration of an automated high-throughput CLIA laboratory for SARS-CoV-2 testing on a large urban campus

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…Social distancing, use of masks and immunization are the most effective strategies to control the dissemination of the disease 5 – 7 . Therefore, populational testing is critical to accurately monitor the course of the disease and drive policies for the mitigation of the disease outcomes 8 .…”

Section: Introductionmentioning

confidence: 99%

On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination

Fernandes-Siqueira

Ferreira

Sousa

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The Covid-19 pandemic, caused by SARS-CoV-2, has resulted in over 6 million reported deaths worldwide being one of the biggest challenges the world faces today. Here we present optimizations of all steps of an enzyme-linked immunosorbent assay (ELISA)-based test to detect IgG, IgA and IgM against the trimeric spike (S) protein, receptor binding domain (RBD), and N terminal domain of the nucleocapsid (N-NTD) protein of SARS-CoV-2. We discuss how to determine specific thresholds for antibody positivity and its limitations according to the antigen used. We applied the assay to a cohort of 126 individuals from Rio de Janeiro, Brazil, consisting of 23 PCR-positive individuals and 103 individuals without a confirmed diagnosis for SARS-CoV-2 infection. To illustrate the differences in serological responses to vaccinal immunization, we applied the test in 18 individuals from our cohort before and after receiving ChAdOx-1 nCoV-19 or CoronaVac vaccines. Taken together, our results show that the test can be customized at different stages depending on its application, enabling the user to analyze different cohorts, saving time, reagents, or samples. It is also a valuable tool for elucidating the immunological consequences of new viral strains and monitoring vaccination coverage and duration of response to different immunization regimens.

show abstract

“…Social distancing, use of masks and immunization are the most effective strategies to control the dissemination of the disease [5,6,7]. Therefore, populational testing is critical to precisely track and drive policies for mitigation of the dissemination of the disease [8].…”

Section: Introductionmentioning

confidence: 99%

On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination

Fernandes-Siqueira

Abdalla

Sousa

et al. 2022

Preprint

View full text Add to dashboard Cite

The Covid-19 pandemic, caused by SARS-CoV-2, resulted in more than 5 million deaths being one of the biggest challenges the world faces today. Here we present optimizations to all steps of an enzyme-linked immunosorbent assay (ELISA)-based test to detect IgG, IgA and IgM against the trimeric spike (S) protein, receptor binding domain (RBD), and N terminal domain of the nucleocapsid (N-NTD) protein of SARS-CoV-2. We discuss how to determine the specific thresholds for antibody positivity and its limitations according to the antigen used. We applied the assay in a cohort of 126 individuals from Rio de Janeiro, Brazil, consisting of 23 PCR-positive individuals; and 103 individuals without confirmed diagnosis for SARS-CoV-2 infection. To illustrate the differences in serological responses to vaccinal immunization, we applied the test in 18 individuals of our cohort before and after receive ChAdOx-1 nCoV-19 or CoronaVac vaccines. Taken together, our results show that the test can be customized at different stages depending on its application, enabling the user to analyze different cohorts, saving time, reagents, or samples. It also represents a valuable tool for elucidating the immunological consequences of new viral strains and for monitoring vaccination coverage and the duration of response to different immunization regimens.

show abstract

Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster

Cited by 4 publications

References 3 publications

Buildout and integration of an automated high-throughput CLIA laboratory for SARS-CoV-2 testing on a large urban campus

Buildout and integration of an automated high-throughput CLIA laboratory for SARS-CoV-2 testing on a large urban campus

On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination

On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination

Contact Info

Product

Resources

About